asa glp 1 agonist guidelines Glucagon-Like Peptide-1 Receptor Agonists–Health Professional Version GLP-1 RA medications and Anesthesia
Description
Methods This is a cohort study combining several population-wide databases and covering a Spanish population of five million inhabitants, including all adults with obesity who initiated treatment with either GLP-1RA or SGLT-2i for type 2 diabetes from 2015 to 2021
Achieve Sustainable Results With Personalized Care.

Compounded medications are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are emerging glucose-lowering agents primarily used in managing diabetes and obesity

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been studied for their cardiovascular benefits in type 2 diabetes

In recent years, there has been an increase in the morbidity, disability rate,and mortality due to obesity, making ...
